EICHORPublic-registry site landscape for NCT05818085, “Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout”, a Gout study sponsored by Atom Therapeutics Co., Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05818085 (registry record) |
| Study title | Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout |
| Official title | A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout |
| Sponsor | Atom Therapeutics Co., Ltd |
| Condition(s) | Gout |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 57 |
| Site countries | United States, Australia, Georgia, Guatemala, Taiwan |
Patient-friendly overview of this study: eichor.com/study/NCT05818085.
Eichor generates a preliminary site-risk snapshot for NCT05818085 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Gout trials
← Eichor home · All tracked trials · Gout studies · Weekly briefs
